[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transthyretin-mediated-amyloidosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transthyretin-mediated-amyloidosis":59},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100405602",false,"NCT04561518","ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)","ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)","ConTTRibute","Inclusion Criteria:\n\n* Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for the cohort of pre-symptomatic carriers\n* Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis\n\nExclusion Criteria:\n\n* Current enrollment in a clinical trial for any investigational agent","ALL",{"count":18,"type":19},1500,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to:\n\n* Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients\n* Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting\n* Describe disease emergence\u002Fprogression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant",[23,24],"Transthyretin-Mediated Amyloidosis","ATTR Amyloidosis",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45],"RNAi therapeutic","Transthyretin","TTR","Amyloidosis","Hereditary Transthyretin-mediated (hATTR) Amyloidosis","hATTR amyloidosis","Hereditary ATTR amyloidosis","Wild-type amyloidosis","wtATTR amyloidosis","ATTRv amyloidosis","ATTRwt amyloidosis","Polyneuropathy","Familial amyloid polyneuropathies","ATTR","Transthyretin amyloidosis","TTR-mediated amyloidosis","Polyneuropathies","Amyloid neuropathies","Amyloid neuropathies, familial","Amyloidosis, familial","RECRUITING","2026-05-27",{"date":49,"type":50},"2026-05-29","ACTUAL",{"date":52,"type":50},"2020-11-23",{"date":54,"type":19},"2033-12-31",{"name":56,"class":57},"Alnylam Pharmaceuticals","INDUSTRY",40,""]